Recent of biomarker tools
15460 Poster Display Clinical Research – Peri-implant Biology
Background
It is challenging to evaluate oral fluids such as peri-implantitis fluids (PISF). Issues relating to hosts and microbial factors could influence biomarkers expression, release and levels. To attain best results, highly sophisticated methods of analysis are required, with high levels of specificity and sensitivity. We define here a recent chair-side point of care (PoC) lateral-flow immunotests (ImplantSafe®) for detecting active form of MMP-8 in PISF and quantitated by analyse reader(ORALyzer)
Aim/Hypothesis
The aim of study was to show the effectiveness of promising biomarker test (ImplantSafe® ORALyzer®) to differentiate between peri-implantitis and healthy sites.
Material and Methods
Peri-implantitis (n = 29), and healthy controls (n = 32) Both X-rays and clinical parameters have diagnosed, such as probing pocket depth (PPD), bleeding on probing (BOP), and plaque index (PI). All have diagnosed aMMP-8 by ImplantSafe® visual test, and quantitated by ORALyzer®. Similarly, we used immunofluorometric assay (IFMA) for measuring MMP-8 level and with zymographic technique we analyzed the gelatinolytic activity, especially the activities of MMP-2 and -9, from same samples.
Results
Level of aMMP-8 in peri-implantitis site (n = 29) analyzed by ImplantSafe visually positive (+) and quantitated by (ORALyzer®) > 20 ng/ml, (124.60 ± 22.50 ng/ml) differing from health site (n = 32) all having low aMMP-8 visually negative (−) < 20 ng/ml, (18.60 ± 3.46 ng/ml). PoC detected in 5 minutes by ImplantSafe. Likewise, elevated level of aMMP-8 detected by immunofluorometric assay (IFMA) 100% in all peri-implantitis site > 20 ng/ml, whereas all health site were < 20 ng/ml. Any forms or total MMP-9 and -2 did not significantly differentiate peri-implantitis and healthy sites.
Conclusion and Clinical Implications
Based on our results, increased levels of aMMP-8 in PISF was determined to be correlated with clinical and radiographic parameters. ImplantSafe® is and so the first clinically validated commercially available diagnostic, prognostic, and preventive chair-side PoC -technology for peri-implant diseases.
